Thursday, August 13, 2020 9:38:02 PM
Sent from my iPhone
> On Aug 13, 2020, at 4:36 PM, Aaron <mail@revivethera.com> wrote:
>
> ?Hi I've made an investment into your company on the US side of the border and am considering making additional investments in light of the FDA advancement of Bucillamine to Phase 3 trials
>
> 1. Are you planning to get filings current? There are no filings on pink sheets. Any plans to use visibility of Bucillamine if proven efficacy in trials to get off Pink Sheets in US? Yes
> 2. Any updates you can offer to the investment community on how you plan to fund PH 3 ? We have close to 6 mill with warrant money so more than enough to start and can access more later through other sources
> 3. Are there any obstacles you foresee that could delay the start of the PH 3?
>
As discussed in press releases announced
Thanks
> Thank you and congratulations on your progress and good luck in the future
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM